News | August 08, 2014

Biotronik Announces Completion of Enrollment in SFA Arm of the BIOFLEX-I Study

Biotronik Enrollment Completion SFA Arm BIOFLEX-I Study Pulsar-18 4-French

August 8, 2014 — Biotronik announced the completion of patient enrollment in the superficial femoral artery (SFA) arm of its BIOFLEX-I clinical trial, an U.S. Food and Drug Administration (FDA)-approved investigative device exemption (IDE) trial evaluating the use of self-expanding nitinol stents in treating peripheral artery disease (PAD). A total of 296 patients were successfully implanted with the Astron Pulsar and Pulsar-18 stents at 34 centers in the United States, Canada and Europe.

The investigational Pulsar-18 is currently the only self-expanding stent with 4-French introducer sheath compatibility for stent diameters of up to 7 mm and lengths of up to 200 mm. It represents a major advance in the minimally invasive treatment of lower limb disease. Pulsar-18 is designed to have high bending and axial flexibility. Its sufficient chronic outward force and crush resistance are intended to support the vessel while minimizing the risk of inflammatory response that can be triggered by excessive chronic outward force.

“The ability to deliver an SFA stent through a 4-French sheath expands the possibilities for patient treatment,” commented Carlos Mena, Yale New Haven Hospital, New Haven, Conn. Mena is the first U.S. physician to implant a Pulsar-18 stent through a 4-French sheath. “The flexible Pulsar-18 has a low crossing profile that is advantageous, allowing use not only through the 4-French sheath, but also in tight lesions of the SFA.”

Pulsar-18 and 4 French approaches to lower limb interventions were validated in several independent studies, including the 4EVER study, which showed excellent technical success, safety and efficacy for up to two years. In this study, the primary patency of Pulsar-18 was 73.4 percent at 12 months and 69.7 percent at 24 months.1 More recently, the Pulsar-18 stent showed 79.5 percent primary patency 12-month results in the PEACE I all-comers registry. [2]

“Achieving this enrollment goal in the BIOFLEX-I study brings us one step closer to having these novel products available to US physicians for the treatment of lower limb disease,” remarked principal investigator Mark W. Burket, University of Toledo Medical Center, Toledo, Ohio. “The Pulsar-18 and Astron stents will give physicians greater opportunity to treat peripheral vascular disease, thereby improving patient quality of life.”

For more: www.biotronik.com, www.clinicaltrials.gov

References:

1.Bosiers M, et al. Journal of Endovascular Therapy. 2013, 20(6)

2.Lichtenberg M, et al. Journal of Endovascular Therapy. 2014, 21(3)

Related Content

Medtronic Announces Global Resolute Onyx DES One-Month DAPT Study
News | Antiplatelet and Anticoagulation Therapies| August 18, 2017
Medtronic plc announced a global randomized clinical trial that will evaluate one-month dual antiplatelet therapy (DAPT...
Bivalirudin exhibited an improvement in 30-day all-cause mortality when injected post PCI.
News | Antiplatelet and Anticoagulation Therapies| August 16, 2017
August 16, 2017 — A study has examined the efficacies of various post-percutaneous coronary intervention (PCI) bivali
ESC 2017 late breaking trial hot line study presentations.
News | Clinical Study| August 16, 2017
Aug. 16, 2017 – The European Society of Cardiology (ESC) Congress 2017 includes several Hot Line Late-breaking Clinic
News | Drug-Eluting Balloons| August 15, 2017
Surmodics Inc. announced receipt of an investigational device exemption (IDE) from the U.S. Food and Drug...
The Vascular Dynamics MobiusHD device enhances the carotid baroreceptors to reduce resistant hypertension.
News | Hypertension| August 15, 2017
Aug. 15, 2017 — The U.S. Food and Drug Administration (FDA) has approved the Vascular Dynamics Inc.
Abbott Initiates First Clinical Trial of Clip-Based Tricuspid Repair System
News | Heart Valve Technology| August 09, 2017
Abbott announced that the first patient has been enrolled in a clinical study to evaluate a minimally invasive clip-...
Ra Medical Systems Granted Broad Patent for DABRA Catheter
News | Peripheral Artery Disease (PAD)| August 09, 2017
August 9, 2017 — Ra Medical Systems announced that the United States Patent and Trademark Office (USPTO) has granted
Three New Atrial Fibrillation Studies to Feature HeartLight Endoscopic Ablation System
News | Ablation Systems| August 07, 2017
CardioFocus Inc. announced that its HeartLight Endoscopic Ablation System is being featured in three new major clinical...
Overlay Init